. Author manuscript; available in PMC: 2011 Dec 1.

Published in final edited form as: J Cardiothorac Vasc Anesth. 2010 Dec;24(6):913–920. doi: 10.1053/j.jvca.2010.03.024

Table 3.

Preoperative Subject Characteristics according to Development of AKI

Characteristic	No AKI (n=256)	AKI (n=68)	P
Age, years	58.9±12.5	61.0±11.1	0.19
Men, n (%)	165 (64.7)	50 (73.5)	0.17
Black, n (%)	16 (6.3)	3 (4.4)	0.57
Mean arterial pressure, mmHg	93±12	94±11	0.31
Heart rate, bpm	65±14	66±14	0.68
CVP, mmHg	12.1±5	13.7±5	0.03
LVEF, %	57±10	56±10	0.49
Body Mass Index, kg/m²	28.8±6.0	31.5±7.6	0.003
Medical history, n (%)
Diabetes mellitus	57 (22.3)	17 (25.0)	0.63
Hypertension	158 (61.7)	46 (67.6)	0.37
Smoking	51 (19.9)	15 (22.1)	0.70
Medication use preoperative, n (%)
Statin	135 (52.7)	39 (57.4)	0.50
Diuretic	78 (30.5)	28 (41.2)	0.09
ACE inhibitor^*	90 (35.2)	20 (29.4)	0.37
Angiotensin receptor blocker^*	42 (16.4)	14 (20.6)	0.42
Creatinine, mg/dl	1.0±0.2	1.0±0.2	0.93
eGFR, ml/min/1.73m²	78±19	82±25	0.78

ACE inhibitor and angiotensin receptor blocker use was discontinued 4–7 days preoperatively.

ACE, angiotensin converting enzyme; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; CVP, central venous pressure.